Q-omics provides the consensus-scored DSE profile across patient tissues and cancer cell-line models. DSE expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, DSE is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, DSE protein abundance shows 26,991 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, HNSC, and LSCC as cancer lineages where DSE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DSE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DSE survival associations across molecular data types. DSE RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DSE RNA expression–survival associations across cancer types. High DSE expression shows unfavorable associations in STAD, LGG, HNSC and BLCA, but favorable associations in SKCM and LAML. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for DSE RNA expression.
This table summarizes DSE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DSE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DSE shows lower tumor expression in KICH, LIHC, BRCA and UCEC and higher tumor expression in HNSC and CHOL. The HNSC box plot shows higher DSE RNA expression in tumor versus normal tissue (log2 FC = +1.802, t-test p < 0.001).
This table shows molecular features associated with DSE in patient tissues and cancer cell lines. In patient samples, DSE shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DSE RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BREAST.
